WO2010089259A3 - Sustained release composition containing quetiapine - Google Patents

Sustained release composition containing quetiapine Download PDF

Info

Publication number
WO2010089259A3
WO2010089259A3 PCT/EP2010/051098 EP2010051098W WO2010089259A3 WO 2010089259 A3 WO2010089259 A3 WO 2010089259A3 EP 2010051098 W EP2010051098 W EP 2010051098W WO 2010089259 A3 WO2010089259 A3 WO 2010089259A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
composition containing
release composition
pharmaceutical composition
containing quetiapine
Prior art date
Application number
PCT/EP2010/051098
Other languages
French (fr)
Other versions
WO2010089259A2 (en
Inventor
Juergen Heim
Sandra Weigel
Original Assignee
Woerwag R&D Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woerwag R&D Gmbh filed Critical Woerwag R&D Gmbh
Publication of WO2010089259A2 publication Critical patent/WO2010089259A2/en
Publication of WO2010089259A3 publication Critical patent/WO2010089259A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to a sustained release pharmaceutical composition containing quetiapine, a pharmaceutically acceptable salt or a derivative thereof, which allows a once-a-day administration of said sustained release pharmaceutical composition to a patient in need thereof. The present invention is further directed to the use of this composition for the treatment of schizophrenia and acute manic episodes associated with bipolar I disorder, and to a process for preparing the pharmaceutical composition.
PCT/EP2010/051098 2009-02-04 2010-01-29 Sustained release composition containing quetiapine WO2010089259A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151996.7 2009-02-04
EP09151996 2009-02-04

Publications (2)

Publication Number Publication Date
WO2010089259A2 WO2010089259A2 (en) 2010-08-12
WO2010089259A3 true WO2010089259A3 (en) 2011-07-07

Family

ID=42060688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/051098 WO2010089259A2 (en) 2009-02-04 2010-01-29 Sustained release composition containing quetiapine

Country Status (1)

Country Link
WO (1) WO2010089259A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201008261A1 (en) * 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Controlled release quetiapine formulations
WO2014155387A1 (en) * 2013-03-24 2014-10-02 Tushar Patel Extended release dosage forms of quetiapine salts
CN103315973B (en) * 2013-05-24 2014-05-07 杭州和正医药有限公司 Quetiapine osmotic pump controlled release preparation
CN104688709A (en) * 2015-03-24 2015-06-10 北京世桥生物制药有限公司 Fumaric acid quetiapine composition sustained-release tablet and preparing method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
WO2007086079A2 (en) * 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
WO2008060228A1 (en) * 2006-11-17 2008-05-22 Astrazeneca Ab Extended release formulations comprising quetipine and methods for their manufacture
WO2008090569A1 (en) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
EP2153834A2 (en) * 2008-08-07 2010-02-17 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
WO2010028794A1 (en) * 2008-09-10 2010-03-18 Alfred E. Tiefenbacher Gmbh & Co. Kg Retard tablets containing quetiapine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
RS20070511A (en) 2005-06-29 2009-01-22 Panacea Biotec Ltd., Modified release pharmaceutical compositions and processes thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
WO2007086079A2 (en) * 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
WO2008060228A1 (en) * 2006-11-17 2008-05-22 Astrazeneca Ab Extended release formulations comprising quetipine and methods for their manufacture
WO2008090569A1 (en) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
EP2153834A2 (en) * 2008-08-07 2010-02-17 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
WO2010028794A1 (en) * 2008-09-10 2010-03-18 Alfred E. Tiefenbacher Gmbh & Co. Kg Retard tablets containing quetiapine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF QUETIAPINE", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 1 December 2008 (2008-12-01), XP013128235, ISSN: 1533-0001 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 February 2008 (2008-02-07), XP002633914, Database accession no. 148:151916 *
KUCHEKAR B ET AL: "preformulation and formulation studies of novel pH independent controlled release drug delivery system of quetiapnie fumarate", JOURNAL OF PHARMACY RESEARCH,, vol. 2, no. 1, 1 January 2009 (2009-01-01), pages 110 - 119, XP008135863, ISSN: 0974-6943 *

Also Published As

Publication number Publication date
WO2010089259A2 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
PL2371853T3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2020008616A (en) Sublingual fentanyl spray.
MX2020012868A (en) Methods and compositions for sleep disorders and other disorders.
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2009017837A3 (en) Sublingual fentanyl spray
IL210577A (en) Substituted 1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl acetic acid compound, salt, hydrate and solvate thereof, a pharmaceutical composition, the compound, salt, hydrate, solvate or pharmaceutical composition for use as a medicament or for use in a method of treatment, use of the compound, salt, hydrate, solvate, or pharmaceutical composition in the manufacture of a medicament and a process for preparing a composition
NZ589445A (en) Rasagiline for parkinson's disease modification
WO2008149382A8 (en) Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
MX2011012122A (en) Thiophene derivatives.
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
MX347106B (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone.
HK1157337A1 (en)
MX362133B (en) Preparation of high-purity gadobutrol.
SG176628A1 (en) Aminopyrrolidinone derivatives and uses thereof
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
IL197575A (en) Method for the expansion of adult stem cells from blood, use thereof for the preparation of medicament for the treatment of lesions and pharmaceutical composition comprising said adult stem cells
CY1115725T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BETA-AMYLOIDIC DISEASES AND CONCLUSIONS
WO2009140341A3 (en) Atorvastatin compositions
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
EP2241310A3 (en) Modified release formulations of emoxypine
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10701546

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10701546

Country of ref document: EP

Kind code of ref document: A2